Innovation Articles

  1. Rethinking Tau Biology: The Future Of Neurodegenerative Drug Discovery 3/19/2026

    We caught up with Melissa Murray, Ph.D., and Amy Rommel, Ph.D., to discuss tau-associated neurodegenerative diseases.

  2. MicroRNA Therapeutics In Metabolic Liver Disease: Context-Driven Drug Discovery 3/12/2026

    Realizing the therapeutic potential of miRNAs in liver disease requires confronting a problem the field has not fully reckoned with.

  3. Viral Coinfections: Emerging Challenges In Modern Drug Discovery 3/11/2026

    Viral coinfection is a phenomenon more complex than just the concurrency or sequential infection with multiple viruses in the same host. 

  4. Hope For Non-Hallucinogenic Neuroplastogens 3/9/2026

    We caught up with Joseph Tucker, Ph.D., to discuss Enveric Bioscience’s focus on developing non-hallucinogenic neuroplastogenic compounds.

  5. Video Spotlight: Harvard's Alice Stanton On Engineering Integrated Human-Derived miBrain Organoid Models 3/3/2026

    Alice Stanton, PhD, member of the faculty, Harvard Medical School, engineered the first 3D immuno-glial-neurovascular human multicellular integrated brain (miBrain) model. In this video spotlight interview, Dr. Stanton shares her journey into science and neural organoid research.

  6. The Matchmaker Modality: Engineering Event-Driven Pharmacology With Induced Proximity 2/24/2026

    Induced proximity has evolved into a versatile platform with the potential to change drug discovery, but challenges still remain.

  7. A State Of Stress: Developing Therapeutics Rooted In Cell Behavior 2/24/2026

    We caught up with Yerem Yeghiazarians, CEO of Soley Therapeutics, to discuss how capturing the complexity of disease requires going beyond a single target.

  8. Beyond KRAS G12C: New Approaches For Drugging The Undruggable 2/20/2026

    RAS was considered among the holy grail of oncology targets, but over the past decade, this has started to change. A second wave is making its way through R&D to address current shortcomings.

  9. Building Inclusivity Into Early-Stage Preclinical Drug Discovery 2/13/2026

    Systematically reporting both ancestry and sex as standard biological variables may foster more representative and translationally relevant approaches to drug discovery.

  10. From Cyclization To The Clinic: The Rising Era Of Cyclic Peptide Therapeutics 1/28/2026

    The pharmaceutical industry is currently experiencing a golden era for cyclic peptide therapeutics.